Daniel Barenboim, Parkinson's disease
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
Approval of Onapgo (apomorphine hydrochloride) marks the first and only subcutaneous apomorphine infusion device for managing ...
The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease seve ...
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...
AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...
Argentine-born conductor and pianist Daniel Barenboim, KBE, confirmed that he has Parkinson's Disease but nevertheless intends to “maintain as many musical engagements as possible.” ...
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback